arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

Cadrenal Therapeutics, Inc.

CVKD

$1.88 ▼ -0.07 (-3.59%) at close

17 Visible periods

21 Metrics

Absolute Benchmarks

Price Chart

Health

Weak

Bearish Absolute basis

auto_awesome

Analytical Summary

On an absolute basis, Cadrenal Therapeutics, Inc. shows weak fundamentals, weighed down by Return on Invested Capital and FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $4.5M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -110.5% ↘

FCF / Share $-1.25

Trailing P/E —

Price / Book 2.6x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 6, 2026.

17-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-2.50M

↑ +35.1% —

FCF / Share Free cash flow per share

$-1.25

↑ +50.6% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Invested CapitalReturn on Invested Capital of -388.3% is weak on an absolute basis (target > 10%)
FCF / Net IncomeFCF / Net Income of 0.95x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality ↑

Dividend History

Dividend / share · sourced from SEC filings

$16.50 Latest / share

+0.0% YoY

+0.0% 2-yr CAGR

FY 2022

FY 2023

$16.50

FY 2024

$16.50

FY 2025

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗
EPS Growth YoY (%)	50.2% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	59.6% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	39.9% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-1146.7% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-1990.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-378.1% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-3014.3% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-66.7% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	79.2% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-15.9% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	46.2% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-28.6% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-2300.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	35.1% Excellent ↑ Excellent Improving Year-over-year change in net income	27.4% Excellent ↑ Excellent Improving Year-over-year change in net income	-11.5% Weak ↑ Weak Improving Year-over-year change in net income	-53.3% Weak ↑ Weak Improving Year-over-year change in net income	-131.2% Weak ↑ Weak Improving Year-over-year change in net income	-266.0% Weak ↓ Weak Declining Year-over-year change in net income	-132.3% Weak ↓ Weak Declining Year-over-year change in net income	-138.6% Weak ↓ Weak Declining Year-over-year change in net income	67.9% Excellent ↑ Excellent Improving Year-over-year change in net income	77.2% Excellent ↑ Excellent Improving Year-over-year change in net income	-1.0% Weak ↑ Weak Improving Year-over-year change in net income	-99.7% Weak Weak Year-over-year change in net income	-2828.7% Weak Weak Year-over-year change in net income	—	—	—	—
FCF Growth YoY (%)	50.6% Excellent Excellent Year-over-year change in free cash flow	—	—	—	-2099.1% Weak Weak Year-over-year change in free cash flow	—	—	—	12.5% Fair Fair Year-over-year change in free cash flow	—	—	—	-2150.9% Weak Weak Year-over-year change in free cash flow	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗
FCF / Net Income (x)	1.20x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	1.21x Good Good Free cash flow relative to reported net income Optimal: > 1x	0.43x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	1.10x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	0.61x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	0.27x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.06x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.41x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.25x Weak Weak Free cash flow relative to reported net income Optimal: > 1x

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗
Return on Invested Capital (%)	-110.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-88.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-79.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-68.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-50.8% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-45.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-57.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-48.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-22.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-13.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-10.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-25.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-81.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	15.3% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	65.1% Excellent → Excellent Stable Return earned on debt + equity capital invested Optimal: > 10%	56.8% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	79.6% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%
Return on Capital (%) (%)	-87.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-70.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-66.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-62.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-49.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-42.3% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-52.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-45.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-24.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-14.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-12.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-28.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-93.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	-138.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—
Return on Common Equity (%) (%)	-138.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1026%)	-111.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-840%)	-98.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-755%)	-85.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-669%)	-62.9% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-519%)	-56.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-475%)	-70.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-570%)	-59.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-500%)	-26.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-279%)	-14.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-199%)	-11.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-179%)	-31.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-311%)	-127.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-948%)	90.2% Excellent → Excellent Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+502%)	87.0% Excellent → Excellent Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+480%)	74.9% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+399%)	104.4% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+596%)

⚖️ Is the balance sheet risky? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗
Interest Coverage (x)	—	—	—	—	—	—	—	—	—	—	—	—	-1188.52x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	—	-71.82x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-74.83x Weak Weak Operating income divided by interest expense Optimal: > 5x	-81.94x Weak Weak Operating income divided by interest expense Optimal: > 5x
Net Debt (USD)	$-2.31M	$-4.01M	$-3.86M	$-5.57M	$-7.34M	$-10.02M	$-4.36M	$-5.04M	$-6.57M	—	$-9.11M	—	—	$-32.59K	—	—	—

📊 What does each share earn? 7 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗
Basic EPS, GAAP (USD)	$-1.04	$-1.41	$-1.31	$-1.87	$-2.09	$-3.49	$-2.18	$-0.15	$-0.10	$-0.73	$-0.07	$-0.09	$-0.48	$-0.63	$-0.13	$-0.07	$-0.02
Free Cash Flow per Share (USD)	$-1.25	—	$-1.15	$-1.54	$-2.52	—	—	—	$-0.11	—	—	—	$-0.13	—	$-0.05	$-0.06	$-0.01
Dividend per Share (USD)	—	$0.00	$0.00	$0.00	$16.50	—	—	—	—	—	—	—	—	—	—	—	—
Book Value per Share (USD)	$0.72	$1.17	$1.33	$2.14	$3.20	$4.17	$2.76	$0.25	$0.39	$8.86	$0.67	$0.27	$0.35	$-0.68	$-0.15	$-0.09	$-0.02
Tangible Book Value per Share (USD)	$0.72	$1.17	$1.33	$2.14	$3.20	$4.17	$2.76	$0.25	$0.39	$8.86	$0.67	$0.27	$0.35	$-0.68	$-0.15	$-0.09	$-0.02
Basic Weighted Avg Shares (shares)	2.41M	—	2.04M	1.96M	1.84M	—	1.10M	16.01M	16.01M	—	15.40M	11.72M	10.77M	—	8.04M	7.72M	7.50M
Dividend Payout Ratio (%)	—	0.0% Excellent ↑ Excellent Improving Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent ↑ Excellent Improving Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent Excellent Dividends paid as a percentage of earnings Optimal: 30-60%	-789.5% Excellent Excellent Dividends paid as a percentage of earnings Optimal: 30-60%	—	—	—	—	—	—	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗
Working Capital (USD)	$1.79M	$2.73M	$2.73M	$4.29M	$6.10M	$7.43M	$3.41M	$3.98M	$6.17M	$7.67M	$8.71M	$3.14M	$4.04M	$-606.88K	—	—	—
Total Equity (USD)	$1.80M	$2.74M	$2.73M	$4.30M	$6.11M	$7.44M	$3.41M	$3.99M	$6.19M	$7.69M	$8.75M	$3.18M	$4.07M	$-5.55M	$-1.18M	$-670.84K	$-169.15K

📋 What is driving earnings? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗
Depreciation Expense (USD)	$555.00	$555.00	$401.00	$401.00	$5.52K	$407.00	$407.00	$470.00	$597.00	$597.00	$597.00	$597.00	$190.00	$760.00	$506.00	—	—
Net Income, GAAP (USD)	$-2.50M	$-3.04M	$-2.69M	$-3.67M	$-3.85M	$-4.19M	$-2.41M	$-2.39M	$-1.66M	$-1.14M	$-1.04M	$-1.00M	$-5.17M	$-5.01M	$-1.03M	$-502.14K	$-176.65K
Operating Cash Flow (USD)	$-3.00M	$-2.57M	$-2.36M	$-3.03M	$-4.65M	$-1.79M	—	—	$-1.84M	$-694.45K	—	—	$-1.41M	$-290.22K	$-417.71K	$-453.14K	$-43.70K

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 17 quarters

Cadrenal Therapeutics, Inc.

Analytical Summary

17-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Dividend History

Statement lens

Benchmark Lens

Benchmarks unavailable

Compare CVKD with peers